芬兰与瑞典生物初治中重度银屑病患者晚期系统药物治疗的持续性:一项回顾性登记队列研究
该回顾性登记队列研究纳入芬兰和瑞典生物初治中重度斑块状银屑病患者,评估2008-2020年间启动的多种生物制剂和阿普斯特的治疗持续性。主要分析(芬兰2018-2020年,709例)显示古塞奇尤单抗和乌司奴单抗的1年持续治疗率最高(分别为90%和85%),且古塞奇尤单抗的停药率低于其他研究药物。
要点
- 古塞奇尤单抗和乌司奴单抗1年持续治疗率最高(90%和85%)。
- 古塞奇尤单抗停药率低于其他研究药物。
- 治疗持续性反映长期疗效与耐受性。
核心结论
- 古塞奇尤单抗和乌司奴单抗在生物初治中重度斑块状银屑病患者中显示出高持续治疗率,且停药率较低。
研究设计与样本
- 回顾性登记队列研究,纳入芬兰和瑞典2008-2020年启动治疗的生物初治中重度斑块状银屑病患者(≥18岁)。
- 主要分析基于芬兰2018-2020年709例患者,以古塞奇尤单抗为参照比较停药率。
- 扩展队列分析包括芬兰2745例和瑞典10970例生物初治患者。
主要发现
- 芬兰主要分析中,古塞奇尤单抗和乌司奴单抗1年持续治疗率分别为90%和85%。
- 扩展队列分析观察到可比结果。
- 芬兰古塞奇尤单抗治疗患者的停药率低于其他研究药物。
临床怎么用
- 在选择生物制剂时,除疗效外需考虑可行性对治疗持续性的影响。
局限性
- 部分生物制剂因样本量有限(n<20)被排除在持续性分析之外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plaque psoriasis (PsO) requires long-term treatment for symptom control and remission; thus, a long-term pharmacological intervention is necessary. Treatment persistence reflects long-term therapeutic effectiveness and tolerance. OBJECTIVES: This study investigates drug persistence and compares treatment discontinuation rates across biologic agents and apremilast used by PsO patients in Finland and Sweden. METHODS: This retrospective register-based cohort study included bio-naïve patients (≥18 years) with moderate-to-severe PsO, who initiated treatment with abatacept, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab or apremilast during 2008-2020 in Finland or Sweden. The main analysis evaluated persistence (based on duration of continuous treatment) and compared rates of treatment discontinuation using guselkumab as reference drug, during 2018-2020 in Finland. Treatment discontinuation was assessed by survival analysis of the time to first drug discontinuation, including switching to other study drugs. Due to limited sample size (n < 20), certain biologics (abatacept, brodalumab, certolizumab pegol, etanercept, golimumab, risankizumab and tildrakizumab) were excluded from the persistence analysis. RESULTS: In Finland, 709 patients fulfilled the inclusion criteria during 2018-2020 for the main analysis. The highest persistence was observed for guselkumab and ustekinumab with 90 and 85% of treated patients, respectively, continuing treatment for ≥1 year. Comparable results were observed in the expanded cohort analysis (index starting in 2008; 2745 bio-naïve patients in Finland and 10,970 in Sweden). Furthermore, patients treated with guselkumab in Finland showed lower treatment discontinuation rates compared to other study drugs. CONCLUSION: Guselkumab and ustekinumab demonstrated high persistence as measured by continued treatment for at least 1 year. Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.
引用
- Tskhvarashvili G, Aher K, Sveide I, et al. Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden. J Eur Acad Dermatol Venereol. 2024. PMID: 39092632. doi:10.1111/jdv.20198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。